CAPTRUST Financial Advisors
ANTX icon

CAPTRUST Financial Advisors’s AN2 Therapeutics ANTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137K Hold
40,000
– – ﹤0.01% 2757
2025
Q4 		$45.6K Hold
40,000
– – ﹤0.01% 2686
2025
Q3 		$50.8K Hold
40,000
– – ﹤0.01% 2562
2025
Q2 		$42.4K Buy
40,000
+30,000
+300% +$35.8K ﹤0.01% 2442
2025
Q1 		$13.6K Sell
10,000
-18,667
-65% -$23.5K ﹤0.01% 2330
2024
Q4 		$39.6K Hold
28,667
– – ﹤0.01% 2251
2024
Q3 		$30.7K Hold
28,667
– – ﹤0.01% 2256
2024
Q2 		$61.6K Hold
28,667
– – ﹤0.01% 2136
2024
Q1 		$93.2K Hold
28,667
– – ﹤0.01% 2065
2023
Q4 		$587K Hold
28,667
– – ﹤0.01% 1634
2023
Q3 		$461K Buy
+28,667
New +$325K ﹤0.01% 1696

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

CAPTRUST Financial Advisors's ANTX Position: Q1 2026 in Review

CAPTRUST Financial Advisors held its AN2 Therapeutics (ANTX) position steady in Q1 2026 at 40,000 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #2757.

CAPTRUST Financial Advisors first reported a position in ANTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $587K in Q4 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • CAPTRUST Financial Advisors held 40,000 shares of AN2 Therapeutics worth $137K as of Q1 2026.
  • CAPTRUST Financial Advisors left its AN2 Therapeutics share count unchanged in Q1 2026.
  • AN2 Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2757 holding.
  • CAPTRUST Financial Advisors first reported a position in AN2 Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • CAPTRUST Financial Advisors's AN2 Therapeutics position peaked at $587K in Q4 2023.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.